Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Active, not recruiting
Agios Pharmaceuticals, Inc.
Phase 1
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of
AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Active, not recruiting
Institut de Recherches Internationales Servier
Phase 1
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of
AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Completed
Agios Pharmaceuticals, Inc.
Phase 1
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,
pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that
harbor an IDH1 and/or IDH2 mutation
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Active, not recruiting
Agios Pharmaceuticals, Inc.
Phase 1
Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in
resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Active, not recruiting
Institut de Recherches Internationales Servier
Phase 1
Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in
resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
